Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.

Type 2 Diabetes Mellitus and COVID-19: A Narrative Review.
复制标题

DOI:
10.3389/fendo.2021.609470
复制
发表时间:
2021
影响因子:
5.2
通讯作者:
Argano C
Argano C
中科院分区:
医学2区
文献类型:
--
作者:
Corrao S;Pinelli K;Vacca M;Raspanti M;Argano C

文献摘要

参考文献

被引文献

相似文献

由严重急性呼吸道综合征冠状病毒2型(SARS-CoV-2)引起的冠状病毒病(COVID-19)大流行已涉及1亿多人,其中200多万人死亡。糖尿病是全球最普遍的慢性疾病之一,显著增加了COVID-19患者的住院和死亡风险。在这篇综述中,我们讨论了糖尿病患者COVID-19感染的患病率、病理生理机制和结局。我们提出了在糖尿病患者中使用处方药物的理由,并提出了一些实用的临床建议,以应对此类患者的COVID-19。
The pandemic of coronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has involved more than one hundred million individuals, including more than two million deaths. Diabetes represents one of the most prevalent chronic conditions worldwide and significantly increases the risk of hospitalization and death in COVID-19 patients. In this review, we discuss the prevalence, the pathophysiological mechanisms, and the outcomes of COVID-19 infection in people with diabetes. We propose a rationale for using drugs prescribed in patients with diabetes and some pragmatic clinical recommendations to deal with COVID-19 in this kind of patient.
DOI: 10.1038/nrmicro.2016.81
发表时间: 2016-08
期刊: Nature reviews. Microbiology
影响因子: --
作者:
de Wit E;van Doremalen N;Falzarano D;Munster VJ
通讯作者: Munster VJ
DOI: 10.2337/dc20-1444
发表时间: 2021-01
期刊: Diabetes care
影响因子: 16.2
作者:
Dennis JM;Mateen BA;Sonabend R;Thomas NJ;Patel KA;Hattersley AT;Denaxas S;McGovern AP;Vollmer SJ
通讯作者: Vollmer SJ
DOI: 10.3389/fendo.2020.600439
发表时间: 2020
影响因子: 5.2
作者:
Crouse AB;Grimes T;Li P;Might M;Ovalle F;Shalev A
通讯作者: Shalev A
DOI: 10.1016/j.dsx.2020.04.019
发表时间: 2020-07-01
影响因子: 10
作者:
Cure, Erkan;Cure, Medine Cumhur
通讯作者: Cure, Medine Cumhur
DOI: 10.1016/j.redar.2020.07.003
发表时间: 2020-10-01
影响因子: 1.3
作者:
Ferrando, C.;Mellado-Artigas, R.;Hernandez-Sanz, M. L.
通讯作者: Hernandez-Sanz, M. L.